Alzheimer’s disease is linked to the build-up of an abnormal protein in the brain called amyloid beta. Early on, this process doesn’t cause any obvious symptoms. But later, cognitive problems such as memory loss may emerge. The question is, could targeting amyloid beta prevent this?
To answer this question and more, we need your help. We’re looking for people to join a clinical research study called SKYLINE. The SKYLINE Study will evaluate this investigational drug that targets amyloid beta. To take part, you must be between the ages of 60-80 years old and not be experiencing any memory or thought-processing problems. You cannot be diagnosed with Mild Cognitive Impairment (MCI), Alzheimer’s, or dementia.
If you’re interested in taking part, we’d like to first conduct some screening assessments to make sure that you and the study are a good fit (together). For example, we’d measure the amount of amyloid beta in your brain, as only people with a certain level can join this study. If you are eligible, then you’ll be officially invited to join the study. Once you join, you’ll receive subcutaneous (under the skin) injections containing the study medication (either the investigational drug or a placebo). A placebo looks just like the investigational drug, but contains no active ingredients.
Are You Willing To Learn More About Your Risk?
For the first 9 months of SKYLINE, the amount of study medication will gradually increase until it reaches the target dose. After 9 months, you’ll then follow your chosen study treatment schedule of one injection of study medication every week, or two injections, at the same time, every two weeks, for the remaining 43 months. This may sound like a long time, but it can be many years before someone with rising levels of amyloid beta begins to display any outward signs.
Please be aware that participants who experience Alzheimer’s symptoms (and have reached the target dose of the study medication) will be given the investigational drug, even if they were given it before.
If this study sounds interesting to you or someone you know, please contact us today for a confidential and no-obligation chat. We’re particularly interested in hearing from people with a family history of dementia, and participation is entirely voluntary. It’s also worth noting that all study medication and assessments would be provided to you at no cost, and health insurance is not required.